Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 17Carcinoma, Renal Cell 14Neoplasms 12Neoplasm Metastasis 9Neuroendocrine Tumors 7Head and Neck Neoplasms 7Kidney Neoplasms 6Pancreatic Neoplasms 5Prostatic Neoplasms 4Lung Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Waldenstrom Macroglobulinemia 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Somatostatinoma 2Pheochromocytoma 2Paraganglioma 2Neuroectodermal Tumors, Primitive 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Insulinoma 2Hodgkin Disease 2

Interventions

Rituximab 4Etoposide 3Cyclophosphamide 3cobomarsen 2Vincristine 2Prednisone 2Ifosfamide 2Doxorubicin 2Carboplatin 2Brentuximab Vedotin 2ponatinib 1pomalidomide 1ibritumomab tiuxetan 1fludarabine 1dacetuzumab 1Vorinostat 1Melphalan 1Imatinib Mesylate 1Everolimus 1DTRMWXHS-12 1Cytarabine 1Carmustine 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphatic Diseases × Everolimus × Clear all
NCT04305444 2025-01-08

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Zhejiang DTRM Biopharma

Phase 2 Terminated
55 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡